Removed at the end of December the Ministry of Health regulations and other reforms with the new Clinical Research in the period 2009-2010 the amount of annual investment for drug research, 100 million dollars per year is estimated to be over.
Researchers in the Pharmaceutical Companies Association (AİFD) according to the study, the majority of diseases including cancer, 7 thousand 500 new products in the world pharmaceutical market research takes over.
In this study, a molecule of the drug into clinical research for 10-15 years, Turkey's medical, scientific and economic development by contributing to the scientific environment will ensure more effective representation was given to the prediction.
Turkey's clinical research has the potential to draw attention, while on this issue the necessary arrangements, as well as enthusiastic and experienced researchers, international recognition and accreditation of research centers, and patients with the potential addition of the state, as well as pharmaceutical industry nün be willing to invest the saved.
-TURKEY, ISRAEL AND COUNTRIES LIKE GREECE BACK in -
According to the study, despite all this potential, the number of clinical research in terms of Turkey's population is much lower than Israel, even in countries such as Greece and Switzerland are in the back.
Accordingly, last year in Germany with a population of 83 million 4 thousand 364, with a population of 64 million 3 thousand 752 in France, 60 million people in the UK with 3 bin 207, with 58 million population in Italy 2 bin 406, with 43 million population of Spain ' or 2 thousand 98 thousand 307 in Poland with 39 million inhabitants, 144 million population and 951 clinical research done in Russia.
2 thousand in Israel with a population 7'şer to 780 million, 441 thousand in Switzerland, with 11 million population in Greece and 560 are carried out clinical research, clinical research in Turkey, only 462 were made.
Clinical research, designated as a national policy of strategic areas to be in the running, as compatible with EU directives out of the new regulations, drug development in the country open to competition all over the world can point to.
- $ 100 million of''BULUR'' -
Merck Sharp Dohme Pharmaceuticals for Health Policy, Access, and Director of Corporate Communications Jeffrey Kemprecos, despite adverse conditions, in 2008 in Turkey, the clinical research of innovative pharmaceutical industry has increased at a rate of 30-40 percent.
That's it in a short time to experience such an increase, biotechnology and pharmaceutical industry researchers nün aware of Turkey's potential is there, and even investments in Turkey has started to shift is an indication striking Kemprecos, said:
Very eager''to do clinical research, have placed many hospitals, universities and found a doctor, but, like Greece or Israel, from Turkey to the much smaller amount of investment and research in countries on the number of cases are not reached yet. However, the Regulation of Clinical Research to be removed as we see a big improvement. Current trends continue, the number of clinical research in Turkey may be a short time later to Greece and even 2 times more clinical research may be competitors in Russia are made.''
Merck Sharp in 2008 in Turkey Dohme'un realized that increasing the number of clinical research, this issue seriously in the year 2009 have announced plans to increase the Kemprecos in the direction that has continued as follows:
Clinical research in Turkey, clinicians and institutions''to currently about 40 million dollars per year in the amount of funds are transferred. New clinical research regulations and other reforms in the amount of annual investment in the period 2009-2010, 100 million dollars per year are estimated to be over.''
-''ECONOMIC CRISIS ETKİLEMEZ'' -
Global economic crisis, even though R & D investment continues to be expected, drug companies invest in this type of disclaimer that the opinions expressed in the Kemprecos,''in this area increased Turkish medicine and science to the world will be a support, such as voluntary patients, the development stage promising new treatment methods that can provide controlled access''I was talking.
In 2009 this field will be a turning point indicating Kemprecos,''Turkey's hospitals, universities and human capital issues such as the advantages of having taken into consideration, the private sector, innovative drug development nün that a rapid response is observed to be''
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment